FIRST QUARTER 2022 RESULTS AND HIGHLIGHTS - Q1-22 revenues of $4.2 million, up 128% over Q1-21
- Q1-22 gross margins of $1.4 million, up 266% over Q1-21
- Public reimbursement secured in key provinces for Enerzair, Atectura and Redesca
- $25.0 million convertible debenture financing completed
MONTREAL, March 24, 2022 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today reported its financial results for the first quarter ended January 31, 2022.